Tradewinds Capital Management’s Evogene EVGN Stock Holding History

Tradewinds Capital Management’s Portfolio EVGN Stock Details EVGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-131	Closed	-$101	–	739
2026 Q1	$101	Hold	131	–	–	﹤0.01%	684
2025 Q4	$145	Sell	131 -169	-56%	-$197	﹤0.01%	644
2025 Q3	$343	Hold	300	–	–	﹤0.01%	623
2025 Q2	$384	Buy	+300	New	+$367	﹤0.01%	568

Other funds holding EVGN

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

DSC

Daytona Street Capital Saint Louis, Missouri $137M AUM

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

FDCDDQ

Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $32.7B AUM 35.71% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Tradewinds Capital Management's EVGN Position: Q2 2026 in Review

Tradewinds Capital Management sold out of Evogene (EVGN) in Q2 2026, closing a stake of 131 shares — an estimated $101 sold.

Tradewinds Capital Management first reported a position in EVGN in Q2 2025 and held it in 4 quarters. The position peaked at $384 in Q2 2025. 13 funds tracked by Wall St. Rank hold EVGN as of Q2 2026.

Tradewinds Capital Management reported no remaining Evogene position as of Q2 2026 after selling out during the quarter.
Tradewinds Capital Management sold 131 Evogene shares in Q2 2026, an estimated $101.
Tradewinds Capital Management first reported a position in Evogene in Q2 2025 and held it in 4 quarters.
Tradewinds Capital Management's Evogene position peaked at $384 in Q2 2025.
13 funds tracked by Wall St. Rank held Evogene as of Q2 2026.

Based on Tradewinds Capital Management's 13F filing for Q2 2026, filed 24 Jul 2026.